Welcome to the UK and Éire Glaucoma Society website.
UK and Éire Glaucoma Society (UKEGS) is a non-profit national scientific society, and part of Glaucoma UK, which aims to:
We’re excited to confirm that Professor Gus Gazzard, UKEGS President, will be hosting a face-to-face conference in London on 22 and 23 November 2023.
The UKEGS annual conference is an opportunity to network, share the latest research and hear from inspiring speakers.
We’ve got more exciting news to share with you soon about speakers, exhibitors, and tickets. To keep up to date with all the latest news, sign up to email updates by becoming a UKEGS member. Click on the tab titled “Become a UKEGS member” on this page and fill out the form to do so.
The conference will be held at No. 8 Northumberland Avenue London, WC2N 5BY. It is a lovely venue which is just a few minutes’ walk from Charing Cross underground station and Waterloo overground train station.
UKEGS proudest achievement is its annual conference aimed mainly at the ophthalmology community, but increasingly of interest to optometrists and others. The conference is usually held over two days towards the end of each year and is hosted in the hometown of the current President.
The 2023 conference will be held in London, the hometown of the current President, Prof Gus Gazzard. Details about the date and venue will be announced shortly.
The RCOphth and UKEGS have collaboratively developed a clinical tool for classification of patients with glaucoma into strata of risk for significant future sight loss and an estimate of resource requirement for managing the patient. The tool acknowledges diagnosis, stage of disease, complexity of disease, rate of disease progression, life expectancy, ocular and systemic comorbidities, dependency and socio-economic deprivation. The eye-level classification should be used to stratify patients according to the worse eye which has remaining useful vision, for which the patient is willing to undergo treatment to retain sight.
This guidance provides pragmatic advice on recommencing care for glaucoma patients based on clinical expertise from a variety of clinical settings around the UK. The scope of this document is to provide advice for the ‘recovery phase’ rather than the acute lockdown phase. We anticipate this phase will cover perhaps the next six months or so. Some of the points will be germane to longer term ‘post COVID-19’ services.
Glaucoma UK and UKEGS co-fund a glaucoma research award of £50,000 – £70,000 for high quality research that enhances the detection and treatment of glaucoma and improves patients’ quality of life.